- Home
- NEWT vs ANNX Comparison
NEWT vs ANNX Comparison
Compare NEWT & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- ANNX
- Stock Information
- Founded
- NEWT 1998
- ANNX 2011
- Country
- NEWT United States
- ANNX United States
- Employees
- NEWT N/A
- ANNX N/A
- Industry
- NEWT Major Banks
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- NEWT Finance
- ANNX Health Care
- Exchange
- NEWT Nasdaq
- ANNX Nasdaq
- Market Cap
- NEWT 300.3M
- ANNX 334.1M
- IPO Year
- NEWT N/A
- ANNX 2020
- Fundamental
- Price
- NEWT $10.26
- ANNX $2.92
- Analyst Decision
- NEWT Hold
- ANNX Strong Buy
- Analyst Count
- NEWT 4
- ANNX 4
- Target Price
- NEWT $13.25
- ANNX $13.00
- AVG Volume (30 Days)
- NEWT 222.7K
- ANNX 1.9M
- Earning Date
- NEWT 10-29-2025
- ANNX 11-10-2025
- Dividend Yield
- NEWT 7.47%
- ANNX N/A
- EPS Growth
- NEWT 32.88
- ANNX N/A
- EPS
- NEWT 2.23
- ANNX N/A
- Revenue
- NEWT $380,364,000.00
- ANNX N/A
- Revenue This Year
- NEWT N/A
- ANNX N/A
- Revenue Next Year
- NEWT $12.56
- ANNX N/A
- P/E Ratio
- NEWT $4.56
- ANNX N/A
- Revenue Growth
- NEWT 20.21
- ANNX N/A
- 52 Week Low
- NEWT $9.12
- ANNX $1.29
- 52 Week High
- NEWT $15.41
- ANNX $6.93
- Technical
- Relative Strength Index (RSI)
- NEWT 39.01
- ANNX 45.55
- Support Level
- NEWT $10.07
- ANNX $2.66
- Resistance Level
- NEWT $10.36
- ANNX $3.03
- Average True Range (ATR)
- NEWT 0.39
- ANNX 0.24
- MACD
- NEWT -0.00
- ANNX -0.04
- Stochastic Oscillator
- NEWT 17.61
- ANNX 26.98
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.